PROGRESS IN GLOBAL TB CONTROL

Slides:



Advertisements
Similar presentations
WHO Regional Office for Europe Vaccine preventable diseases and Immunization programme Diphtheria Incidence in the WHO European Region 1990 Source; WHO/UNICEF.
Advertisements

Multidrug- resistant tuberculosis: update Multidrug-resistant TB in the world update October 2012  WHO 2012 © World Health Organization 2012.
Multi-drug Resistant Tuberculosis Hail M. Al-Abdely Consultant, Infectious Diseases, KFSH&RC.
Vaccine in National Immunization Programme Update March 2015.
World Health Organization
TITLE from VIEW and SLIDE MASTER | August 7, |1 | Countries with Hib vaccine in the national immunization programme; and planned introductions *
WHO Regional Office for Europe Vaccine preventable diseases and Immunization programme Measles containing vaccine (MCV1) coverage in the WHO European Region.
The Global Plan to Stop TB, (1)
1 Global and Regional Tuberculosis (TB) update ACSM workshop, Amman, Jordan April 13-17, 2008 Dr. Sevil Huseynova.
World Health Organization
Highlights of New WPV Cases 34 new cases in 5 countries 14 cases (14 W3) but no new district in India Most recent date of onset 03 Oct 1 case (W1) but.
DOTS Expansion: Monitoring Drugs Leopold Blanc TBS, Stop TB WHO, Communicable Diseases.
Evidence and Information for Policy Christopher J.L. Murray Executive Director Evidence and Information for Policy World Health Organization National Capacity.
World Health Assembly 63 Geneva, Suisse May 2010 WORLD HEALTH EDITORS NETWORK Tracking Global Health News: building health literacy Multi-Drug Resistant.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
The revised TB/HIV indicators and update on the process of harmonization Christian Gunneberg MO WHO The 14th Core Group Meeting of the TB/HIV Working Group.
Strategic Information and the Control of Tuberculosis Brian Williams and Chris Dye TB programme, Monitoring and Evaluation, WHO.
Moving ahead with the Stop TB Strategy: where are we today? Dr Mario Raviglione Director, WHO Stop TB Department Joint Meeting of Core Teams and High Burden.
Current Health Concerns: Tuberculosis Saharwash Jamali Hamna Jaffar.
Understanding the impact of disease control: TB epidemiology and the GFATM.
Dr Ral Antic Chair Scientific Committee IUATLD-APR Australia Pre-Conference Workshop 1 National TB Control Program Summary & Remarks.
Global Tuberculosis Control 2007 Did we reach the 2005 targets? Will we achieve the Millennium Development Goals?
Christian Gunneberg, Medical Officer WHO, Geneva STB Department
World Health Organization
Monitoring and Evaluation: A Review of Terms
SAGE 2010 Sampling Distribution
Palliative Care and M/XDR-TB Global burden of M/XDR-TB
financial requirements
Measles disease An acute viral infection spread via respiratory secretions or aerosols Classic manifestations: Maculopapular rash Fever +cough + coryza/conjuctivities.
reporting rate of discarded cases* per 100'000 population**
Ageing Matters Somnath Chatterji Information, Evidence and Research
TUBERCULOSIS, TB/HIV & MDR-TB
اپيدميولوژي و كنترل سِل
სასწავლო კურსი ოჯახის ექიმებისთვის ტუბერკულოზის ადრეული გამოვლენა და მართვა ზოგად საექიმო პრაქტიკაში სასწავლო პროგრამა ხორციელდება საოჯახო მედიცინის პროფესიონალთა.
Monthly Distribution of Wild Poliovirus Cases1,
SAGE 2009 Sampling Distribution
Key issues in DOTS implementation
06/12/2018 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
Countries Having Introduced Hib Vaccine
Countries Having Introduced Hib Vaccine and Infant Hib Coverage, 2010
Sampling Distribution
15/01/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week The boundaries and names shown and the designations used in.
Non-polio AFP Rate July 2014 – June 2015 July 2015 – June 2016
Monthly Distribution of Wild Poliovirus Cases1,
(70 countries or 36%) (23 countries or 12%)
Countries with Genotype data available
Countries Using Hib Vaccine in National Immunization Schedule in 2010 and Countries Approved for GAVI Support for Use from 2011 Onwards Yes (166 countries.
World Health Organization
24/02/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
World Health Organization
Onset of most recent WPV1 Case Number of WPV infected districts
08/04/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
Countries having introduced HepB vaccine
No new positives this week
05/04/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
Most-affected regions in the Russian Federation
08/04/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week The boundaries and names shown and the designations used in.
Mapping Levels of Palliative Care Development: A Global Update
Countries Using Mening Vaccine in National Immunization Schedule 2011
- Use same categories as for bar chart below Introduced Without GAVI
Onset of most recent case Number of infected districts
PROGRESS IN GLOBAL TB CONTROL
Managing TB in the era of HIV
THE GLOBAL EPIDEMIOLOGY OF TUBERCULOSIS WORLD HEALTH ORGANIZATION
Meningitis/Encephalitis Surveillance Countries reporting to WHO Network or with Other (non-WHO Network) Surveillance Activities WHO Network (46 member.
16/05/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
27/08/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
2,100 4,200 1,050 Kilometers < 90% (75 countries or 39%)
World Health Organization
World Health Organization
Presentation transcript:

PROGRESS IN GLOBAL TB CONTROL WITH SPECIAL REFERENCE TO EUROPE CHRIS DYE plus ~200 others WORLD HEALTH ORGANIZATION GENEVA

Tuberculosis in the world, 2002 People infected 2 billion New TB cases 8.6m (138/100K) New ss+ TB cases 3.8m Change incidence rate 0.4%/yr Prevalence HIV in new adult cases 12% Prevalence MDR in new cases 3.2% Deaths from TB (inc HIV) 1.8m (28/100K)

Most TB cases are in India and China < 1 000 1 000 to 9 999 10 000 to 99 999 100 000 to 999 999 1 000 000 or more No Estimate The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. © WHO 2002

Highest TB rates per capita are in Africa 25 to 49 50 to 99 100 to 299 < 10 10 to 24 300 or more No Estimate per 100 000 population The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. © WHO 2002

Tuberculosis in Europe, 2002 People infected 200 m New TB cases 481K (55/100K) New ss+ TB cases 215K (25/100K) Change incidence rate 0.4%/yr Prevalence HIV in new adult cases 4% Prevalence MDR in new cases 5% Deaths from TB (inc HIV) 76K (9/100K)

Estimated TB Incidence Number, All Forms, 2002

Estimated TB Incidence Rates, All Forms, 2002

Global targets for TB control MILLENNIUM DEVELOPMENT GOALS By 2005: 70% case detection, 85% cure By 2015: Halve prevalence and deaths

SURVEILLANCE REPORTS RECEIVED BY 3 OCTOBER 2003

Progress towards 70% case detection under DOTS 80 70 Target 70% 60 50 All smear+ cases Case detection rate (%) 40 Forecast 2002: 30 1.4m smear+ = 37% DDR 20 Smear+ cases DOTS 10 1990 1995 2000 2005 2010 2015 Year

Why are TB cases “undetected”? estimated TB cases all true TB cases cases presenting to health facilities cases presenting to public health facilities cases presenting to DOTS facilities cases correctly diagnosed by DOTS facilities diagnosed cases reported by DOTS facilities

Few Chinese patients diagnosed in, or transferred to, DOTS dispensaries Other Transfer Private clinics Diagnosis Town/village clinics TB hospitals Trad med units General hospitals TB dispensaries 50 100 150 200 Source: 2000 prevalence survey Number of patients

Improving case detection in China 627 patients with TB, seen by health services 100 90 80 70 60 50 Cumulative proportion TB patients (%) 40 30 20 10 Other clinics TB units Private General hospitals Township clinics Traditional medics TB hospitals misdiagnosed source: 2000 prevalence survey

Better treatment in DOTS dispensaries China 2000 prevalence survey 70 TB dispensaries 60 Other units 50 40 Percent patients 30 20 10 Regular Intermittent Interrupted

Dynamics of pulmonary TB in Peru 1980-2000 220 DOTS 1990 200 case finding 180 Pulmonary TB cases/100,000 160 140 120 PTB falling at 6%/yr 100 1980 1985 1990 1995 2000

DOTS reduces prevalence of TB by 37% over a decade in China 250 DOTS Other 200 150 Prevalence culture+ TB/100,000 100 50 1990 2000

WE’RE HALF WAY THERE but not in Europe... Case detection 36/70 Europe Treatment success 83/85

THE DATA CAN TELL US MORE THAN WE KNOW